315 related articles for article (PubMed ID: 20179223)
1. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
Campbell MR; Amin D; Moasser MM
Clin Cancer Res; 2010 Mar; 16(5):1373-83. PubMed ID: 20179223
[TBL] [Abstract][Full Text] [Related]
2. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.
Littlefield P; Liu L; Mysore V; Shan Y; Shaw DE; Jura N
Sci Signal; 2014 Dec; 7(354):ra114. PubMed ID: 25468994
[TBL] [Abstract][Full Text] [Related]
3. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Amin DN; Campbell MR; Moasser MM
Semin Cell Dev Biol; 2010 Dec; 21(9):944-50. PubMed ID: 20816829
[TBL] [Abstract][Full Text] [Related]
4. HER3/ErbB3, an emerging cancer therapeutic target.
Zhang N; Chang Y; Rios A; An Z
Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
[TBL] [Abstract][Full Text] [Related]
5. HER3, serious partner in crime: therapeutic approaches and potential biomarkers for effect of HER3-targeting.
Kol A; Terwisscha van Scheltinga AG; Timmer-Bosscha H; Lamberts LE; Bensch F; de Vries EG; Schröder CP
Pharmacol Ther; 2014 Jul; 143(1):1-11. PubMed ID: 24513440
[TBL] [Abstract][Full Text] [Related]
6. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
[TBL] [Abstract][Full Text] [Related]
7. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches.
Zaczek A; Brandt B; Bielawski KP
Histol Histopathol; 2005 Jul; 20(3):1005-15. PubMed ID: 15944951
[TBL] [Abstract][Full Text] [Related]
8. The role of HER3 in gastric cancer.
Wang L; Yuan H; Li Y; Han Y
Biomed Pharmacother; 2014 Jul; 68(6):809-12. PubMed ID: 25194439
[TBL] [Abstract][Full Text] [Related]
9. Understanding the biology of HER3 receptor as a therapeutic target in human cancer.
Lyu H; Han A; Polsdofer E; Liu S; Liu B
Acta Pharm Sin B; 2018 Jul; 8(4):503-510. PubMed ID: 30109175
[TBL] [Abstract][Full Text] [Related]
10. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER proteins in cancer therapy and the role of the non-target HER3.
Hsieh AC; Moasser MM
Br J Cancer; 2007 Aug; 97(4):453-7. PubMed ID: 17667926
[TBL] [Abstract][Full Text] [Related]
12. HER family in cancer progression: From discovery to 2020 and beyond.
Kumar R; George B; Campbell MR; Verma N; Paul AM; Melo-Alvim C; Ribeiro L; Pillai MR; da Costa LM; Moasser MM
Adv Cancer Res; 2020; 147():109-160. PubMed ID: 32593399
[TBL] [Abstract][Full Text] [Related]
13. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
[TBL] [Abstract][Full Text] [Related]
14. The upgraded role of HER3 and HER4 receptors in breast cancer.
Koutras AK; Fountzilas G; Kalogeras KT; Starakis I; Iconomou G; Kalofonos HP
Crit Rev Oncol Hematol; 2010 May; 74(2):73-8. PubMed ID: 19481955
[TBL] [Abstract][Full Text] [Related]
15. HER3 signaling and targeted therapy in cancer.
Mishra R; Patel H; Alanazi S; Yuan L; Garrett JT
Oncol Rev; 2018 Jan; 12(1):355. PubMed ID: 30057690
[TBL] [Abstract][Full Text] [Related]
16. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
17. Transphosphorylation of kinase-dead HER3 and breast cancer progression: a new standpoint or an old concept revisited?
Menendez JA; Lupu R
Breast Cancer Res; 2007; 9(5):111. PubMed ID: 17983482
[TBL] [Abstract][Full Text] [Related]
18. A critical role for HER3 in HER2-amplified and non-amplified breast cancers: function of a kinase-dead RTK.
Dey N; Williams C; Leyland-Jones B; De P
Am J Transl Res; 2015; 7(4):733-50. PubMed ID: 26064441
[TBL] [Abstract][Full Text] [Related]
19. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
[TBL] [Abstract][Full Text] [Related]
20. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
